Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR

Man Group plc purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 150,688 shares of the company’s stock, valued at approximately $1,536,000. Man Group plc owned 0.09% of Vir Biotechnology as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of VIR. BlackRock Inc. bought a new stake in Vir Biotechnology in the second quarter valued at approximately $210,712,000. ARCH Venture Management LLC bought a new position in shares of Vir Biotechnology during the 2nd quarter worth approximately $129,353,521. GSK plc acquired a new position in shares of Vir Biotechnology during the 4th quarter worth approximately $51,562,000. ADAR1 Capital Management LLC acquired a new position in shares of Vir Biotechnology during the 1st quarter worth approximately $24,593,000. Finally, Pictet Asset Management Holding SA raised its stake in Vir Biotechnology by 10,878.9% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after acquiring an additional 1,467,340 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

VIR has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Leerink Partners lifted their target price on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Finally, Morgan Stanley set a $25.00 price target on shares of Vir Biotechnology in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $21.57.

Vir Biotechnology Price Performance

VIR opened at $11.50 on Thursday. The business has a fifty day simple moving average of $9.68 and a 200 day simple moving average of $9.40. The company has a market capitalization of $1.95 billion, a PE ratio of -6.18 and a beta of 1.63. Vir Biotechnology, Inc. has a 1 year low of $4.75 and a 1 year high of $11.94.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. During the same quarter last year, the business earned ($0.80) EPS. The company’s quarterly revenue was up 19582.5% compared to the same quarter last year. Equities analysts anticipate that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.